Matching mutations in tumours to precision medicine improves survival
Matching mutations in tumours to precision medicine improves survival
Editor’s Choice for May 2018
Incorporating biomarkers into clinical trial design
Clinical management of plasma cell leukaemia
Dose escalation of durvalumab with tremelimumab for metastatic urothelial cancer
Biomarkers of pembrolizumab response in head and neck cancer
Safety indications in mouse models treated with full doses of MEK inhibitors and SHP099
Mechanisms and prospects of a novel CDK9 inhibitor for DLBCL
Front-line therapy of DIPG using IDO inhibitor with radiation and chemotherapy
Impact of microbiome on head and neck cancers
First-in-human trial results of RET targeted BLU-667
Treating RET alterations with novel therapy BLU-667